This single‑arm, pre–post clinical feasibility study evaluated whether adults with newly diagnosed type 2 diabetes, identified through community screening, could be diagnosed, enrolled, and managed at a rural primary healthcare facility using the WHO Package of Essential Noncommunicable Disease Interventions (WHO‑PEN). The primary aim was to assess feasibility across four domains—acceptability, implementation fidelity, practicality, and preliminary clinical signal—after a six‑month programme of care.
The study was conducted at a primary healthcare facility serving Shebedino district in Sidama National Regional State, rural Ethiopia, between September 2024 and February 2025. Thirty‑five adults with newly diagnosed type 2 diabetes were enrolled; diagnoses were made according to WHO and American Diabetes Association criteria following community‑based screening. All 35 participants completed the six‑month follow up, yielding 100% retention for the reported period.
Participants received a six‑month intervention grounded in the WHO‑PEN approach. The package included:
The intervention aimed to follow established primary‑care protocols for noncommunicable disease management in resource‑limited rural settings.
Feasibility was evaluated across four predefined domains: acceptability, implementation fidelity, practicality, and a preliminary clinical signal. The principal clinical endpoint reported was change in HbA1c from baseline to six months. Analyses of continuous changes used the Wilcoxon signed‑rank test; categorical changes in control status used McNemar’s test. The manuscript reports retention and completion rates as indicators of acceptability and practicality.
At enrollment, the cohort had several notable characteristics: 6 of 35 participants (17%) had comorbid hypertension. Five participants (14%) had elevated total cholesterol, while 14 (40%) had low HDL cholesterol. A majority, 24 of 35 (69%), were underweight at baseline. Baseline median HbA1c was 52.0 mmol/mol with an interquartile range (IQR) of 50.0 to 56.0 mmol/mol.
After six months on the WHO‑PEN based programme, median HbA1c decreased to 43.0 mmol/mol (IQR 42.0–46.0), representing a median reduction of 9.0 mmol/mol from baseline. This change was statistically significant (p < 0.001, Wilcoxon signed‑rank test). The proportion of participants meeting the study’s HbA1c control threshold increased from 20 of 35 (57%) at baseline to 30 of 35 (85.7%) at six months; this categorical improvement was statistically significant (p = 0.002, McNemar’s test).
All enrolled participants completed follow up, supporting feasibility in terms of linkage and retention. However, the authors report that medication was not adjusted for some patients with persistent hyperglycaemia despite scheduled reviews. This finding indicates that while linkage and retention were feasible, there were shortcomings in implementation fidelity—specifically, in the application of established medication‑adjustment practices during routine follow up. The authors frame this gap as a priority for strengthening implementation rather than as justification for further efficacy testing.
Ethical clearance was obtained from the Institutional Review Board of Hawassa University, College of Medicine and Health Sciences (Ref. no. IRB/100/16, issued 12 March 2024). Additional administrative approvals were secured from regional and district public health bodies, and written informed consent was obtained from all participants. Financial support was declared from the government of Norway under the NORHED SENUPH‑II programme; the funder did not influence study design, data collection, analysis, interpretation, or the decision to submit the work. The authors state that data are available upon reasonable request.
The study demonstrates that adults with type 2 diabetes identified through community screening can be diagnosed, linked to care, and retained at a rural primary healthcare facility using a WHO‑PEN model, with a substantial and statistically significant improvement in HbA1c over six months. Key limitations include the single‑arm design and absence of a control group, which preclude causal inference about the effect of the intervention. Implementation gaps—particularly the lack of medication adjustment for patients with persistent hyperglycaemia—underscore the need for strengthening routine clinical practice and protocols at the primary care level. These results support feasibility of WHO‑PEN implementation for community‑detected diabetes in rural Ethiopian settings but indicate further work is needed to ensure consistent treatment intensification and full fidelity to guideline‑based care.